| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3192902 | Annals of Allergy, Asthma & Immunology | 2008 | 5 Pages |
Abstract
Limited evidence suggests that for patients who develop angioedema when taking an ACE-I, the risk of development of any subsequent angioedema when taking an ARB is between 2% and 17%; for confirmed angioedema, the risk is 0% to 9.2%. This information will aid clinicians in counseling patients regarding therapy options after development of angioedema due to ACE-Is.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Bret R. MD, Jiun MD, Cecilia P. MD, MPH, Mary M. MD, Kent J. MD, MPH,